Literature DB >> 24463469

The relationship of JAK2(V617F) and acquired UPD at chromosome 9p in polycythemia vera.

L Wang1, S I Swierczek2, L Lanikova2, S J Kim2, K Hickman2, K Walker1, K Wang3, J Drummond1, H Doddapaneni1, J G Reid1, D M Muzny1, R A Gibbs1, D A Wheeler1, J T Prchal2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24463469      PMCID： PMC4532371          DOI： 10.1038/leu.2014.20

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  16 in total

1.  Homologous recombination of wild-type JAK2, a novel early step in the development of myeloproliferative neoplasm.

Authors:  Mathias Vilaine; Damla Olcaydu; Ashot Harutyunyan; Jonathan Bergeman; Mourad Tiab; Jean-François Ramée; Jian-Min Chen; Robert Kralovics; Sylvie Hermouet
Journal:  Blood       Date:  2011-12-08       Impact factor: 22.113

2.  Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia.

Authors:  Alessandro M Vannucchi; Elisabetta Antonioli; Paola Guglielmelli; Alessandro Rambaldi; Giovanni Barosi; Roberto Marchioli; Rosa Maria Marfisi; Guido Finazzi; Vittoria Guerini; Fabrizio Fabris; Maria Luigia Randi; Valerio De Stefano; Sabrina Caberlon; Agostino Tafuri; Marco Ruggeri; Giorgina Specchia; Vincenzo Liso; Edoardo Rossi; Enrico Pogliani; Luigi Gugliotta; Alberto Bosi; Tiziano Barbui
Journal:  Blood       Date:  2007-03-22       Impact factor: 22.113

3.  Hematopoiesis is not clonal in healthy elderly women.

Authors:  Sabina I Swierczek; Neeraj Agarwal; Roberto H Nussenzveig; Gerald Rothstein; Andrew Wilson; Andrew Artz; Josef T Prchal
Journal:  Blood       Date:  2008-07-18       Impact factor: 22.113

4.  Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera.

Authors:  Robert Kralovics; Yongli Guan; Josef T Prchal
Journal:  Exp Hematol       Date:  2002-03       Impact factor: 3.084

5.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.

Authors:  Chloé James; Valérie Ugo; Jean-Pierre Le Couédic; Judith Staerk; François Delhommeau; Catherine Lacout; Loïc Garçon; Hana Raslova; Roland Berger; Annelise Bennaceur-Griscelli; Jean Luc Villeval; Stefan N Constantinescu; Nicole Casadevall; William Vainchenker
Journal:  Nature       Date:  2005-04-28       Impact factor: 49.962

6.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

Authors:  Ross L Levine; Martha Wadleigh; Jan Cools; Benjamin L Ebert; Gerlinde Wernig; Brian J P Huntly; Titus J Boggon; Iwona Wlodarska; Jennifer J Clark; Sandra Moore; Jennifer Adelsperger; Sumin Koo; Jeffrey C Lee; Stacey Gabriel; Thomas Mercher; Alan D'Andrea; Stefan Fröhling; Konstanze Döhner; Peter Marynen; Peter Vandenberghe; Ruben A Mesa; Ayalew Tefferi; James D Griffin; Michael J Eck; William R Sellers; Matthew Meyerson; Todd R Golub; Stephanie J Lee; D Gary Gilliland
Journal:  Cancer Cell       Date:  2005-04       Impact factor: 31.743

7.  Convergent mechanisms of somatic mutations in polycythemia vera.

Authors:  Kai Wang; Sabina Swierczek; Kimberly Hickman; Hakon Hakonarson; Josef T Prchal
Journal:  Discov Med       Date:  2011-07       Impact factor: 2.970

8.  Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression.

Authors:  Thorsten Klampfl; Ashot Harutyunyan; Tiina Berg; Bettina Gisslinger; Martin Schalling; Klaudia Bagienski; Damla Olcaydu; Francesco Passamonti; Elisa Rumi; Daniela Pietra; Roland Jäger; Lisa Pieri; Paola Guglielmelli; Ilaria Iacobucci; Giovanni Martinelli; Mario Cazzola; Alessandro M Vannucchi; Heinz Gisslinger; Robert Kralovics
Journal:  Blood       Date:  2011-04-29       Impact factor: 22.113

9.  A gain-of-function mutation of JAK2 in myeloproliferative disorders.

Authors:  Robert Kralovics; Francesco Passamonti; Andreas S Buser; Soon-Siong Teo; Ralph Tiedt; Jakob R Passweg; Andre Tichelli; Mario Cazzola; Radek C Skoda
Journal:  N Engl J Med       Date:  2005-04-28       Impact factor: 91.245

10.  Recurrent hemizygous deletions in cancers may optimize proliferative potential.

Authors:  Nicole L Solimini; Qikai Xu; Craig H Mermel; Anthony C Liang; Michael R Schlabach; Ji Luo; Anna E Burrows; Anthony N Anselmo; Andrea L Bredemeyer; Mamie Z Li; Rameen Beroukhim; Matthew Meyerson; Stephen J Elledge
Journal:  Science       Date:  2012-05-24       Impact factor: 47.728
View more
  8 in total

Review 1.  Novel insights into the biology and treatment of chronic myeloproliferative neoplasms.

Authors:  Tariq I Mughal; Tiziano Barbui; Omar Abdel-Wahab; Robert Kralovics; Catriona Jamieson; Hans-Michael Kvasnicka; Ann Mullaly; Raajit Rampal; Ruben Mesa; Jean-Jacques Kiladjian; Michael Deininger; Josef Prchal; Rüdiger Hehlmann; Giuseppe Saglio; Richard A Van Etten
Journal:  Leuk Lymphoma       Date:  2014-11-19

2.  Coexistence of gain-of-function JAK2 germ line mutations with JAK2V617F in polycythemia vera.

Authors:  Lucie Lanikova; Olga Babosova; Sabina Swierczek; Linghua Wang; David A Wheeler; Vladimir Divoky; Vladimir Korinek; Josef T Prchal
Journal:  Blood       Date:  2016-09-19       Impact factor: 22.113

Review 3.  Acquired uniparental disomy of chromosome 9p in hematologic malignancies.

Authors:  Linghua Wang; David A Wheeler; Josef T Prchal
Journal:  Exp Hematol       Date:  2015-12-02       Impact factor: 3.084

4.  Clonal evolution revealed by whole genome sequencing in a case of primary myelofibrosis transformed to secondary acute myeloid leukemia.

Authors:  E K Engle; D A C Fisher; C A Miller; M D McLellan; R S Fulton; D M Moore; R K Wilson; T J Ley; S T Oh
Journal:  Leukemia       Date:  2014-09-25       Impact factor: 11.528

Review 5.  SNP Array in Hematopoietic Neoplasms: A Review.

Authors:  Jinming Song; Haipeng Shao
Journal:  Microarrays (Basel)       Date:  2015-12-22

6.  PD-L1 overexpression correlates with JAK2-V617F mutational burden and is associated with 9p uniparental disomy in myeloproliferative neoplasms.

Authors:  Jelena D Milosevic Feenstra; Roland Jäger; Fiorella Schischlik; Daniel Ivanov; Gregor Eisenwort; Elisa Rumi; Michael Schuster; Bettina Gisslinger; Sigrid Machherndl-Spandl; Peter Bettelheim; Maria-Theresa Krauth; Felix Keil; Christoph Bock; Mario Cazzola; Heinz Gisslinger; Robert Kralovics; Peter Valent
Journal:  Am J Hematol       Date:  2022-01-21       Impact factor: 13.265

Review 7.  Cohesin mutations in myeloid malignancies.

Authors:  Johann-Christoph Jann; Zuzana Tothova
Journal:  Blood       Date:  2021-08-26       Impact factor: 25.476

8.  Impact of copy neutral loss of heterozygosity and total genome aberrations on survival in myelodysplastic syndrome.

Authors:  Cecilia C S Yeung; Scott McElhone; Xue Yan Chen; David Ng; Barry E Storer; H Joachim Deeg; Min Fang
Journal:  Mod Pathol       Date:  2017-12-15       Impact factor: 7.842
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.